Sökning: onr:"swepub:oai:DiVA.org:kth-311010" >
Duration of SARS-Co...
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
-
- Marking, Ulrika (författare)
- Karolinska Institutet
-
- Havervall, Sebastian (författare)
- Karolinska Institutet
-
- Greilert-Norin, Nina (författare)
- Karolinska Inst, Dept Clin Sci, Danderyd Hosp, S-18288 Stockholm, Sweden.
-
visa fler...
-
- Ng, Henry (författare)
- Karolinska Inst, Dept Clin Sci, Danderyd Hosp, S-18288 Stockholm, Sweden.;Uppsala Univ, Dept Med Cell Biol, S-75123 Uppsala, Sweden.
-
- Blom, Kim (författare)
- Karolinska Institutet
-
- Nilsson, Peter (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,KTH Royal Inst Technol, Dept Prot Sci, SciLifeLab, S-11428 Stockholm, Sweden.
-
- Phillipson, Mia, 1973- (författare)
- Uppsala universitet,Institutionen för medicinsk cellbiologi,Science for Life Laboratory, SciLifeLab
-
- Hober, Sophia, Professor, 1965- (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi,KTH Royal Inst Technol, Dept Prot Sci, SciLifeLab, S-11428 Stockholm, Sweden.
-
- Nilsson, Charlotta (författare)
- Karolinska Institutet
-
- Mangsbo, Sara, 1981- (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för farmaceutisk biovetenskap
-
- Christ, Wanda (författare)
- Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, S-14152 Stockholm, Sweden.
-
- Klingstrom, Jonas (författare)
- Karolinska Institutet
-
- Gordon, Max (författare)
- Karolinska Institutet
-
- Åberg, Mikael (författare)
- Uppsala universitet,Koagulation och inflammationsvetenskap,Science for Life Laboratory, SciLifeLab,Klinisk kemi
-
- Thalin, Charlotte (författare)
- Karolinska Institutet
-
visa färre...
-
Karolinska Institutet Karolinska Inst, Dept Clin Sci, Danderyd Hosp, S-18288 Stockholm, Sweden (creator_code:org_t)
- 2022-02-24
- 2022
- Engelska.
-
Ingår i: Vaccines. - : MDPI AG. - 2076-393X. ; 10:3, s. 359-
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://www.mdpi.com...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after primary vaccination with homologous adeno-vectored ChAdOx1 nCoV-19 vaccine (ChAd) or heterologous ChAd/BNT162b2 mRNA vaccine (BNT), anti-spike-IgG and SARS-CoV-2 VOC-neutralizing antibody responses were measured in 354 healthcare workers (HCW) at 2 weeks, 3 months, 5 months and 6 months after the second vaccine dose. T-cell responses were investigated using a whole blood interferon gamma (IFN-gamma) release assay 2 weeks and 3 months post second vaccine dose. Two hundred and ten HCW immunized with homologous BNT were enrolled for comparison of antibody responses. In study participants naive to SARS-CoV-2 prior to vaccination, heterologous ChAd/BNT resulted in 6-fold higher peak anti-spike IgG antibody titers compared to homologous ChAd vaccination. The half-life of antibody titers was 3.1 months (95% CI 2.8-3.6) following homologous ChAd vaccination and 1.9 months (95% CI 1.7-2.1) after heterologous vaccination, reducing the GMT difference between the groups to 3-fold 6 months post vaccination. Peak T-cell responses were stronger in ChAd/BNT vaccinees, but no significant difference was observed 3 months post vaccination. SARS-CoV-2 infection prior to vaccination resulted in substantially higher peak GMTs and IFN-gamma levels and enhanced SARS-CoV-2 specific antibody and T cell responses over time. Heterologous primary SARS-CoV-2 immunization with ChAd and BNT elicits a stronger initial immune response compared to homologous vaccination with ChAd. However, although the differences in humoral responses remain over 6 months, the difference in SARS-CoV-2 specific T cell responses are no longer significant three months after vaccination.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- COVID-19
- SARS-CoV-2
- SARS-CoV-2 vaccination
- heterologous
- immune response
- duration
- antibodies
- humoral response
- T-cells
- immunity
- immunology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Vaccines
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Marking, Ulrika
-
Havervall, Sebas ...
-
Greilert-Norin, ...
-
Ng, Henry
-
Blom, Kim
-
Nilsson, Peter
-
visa fler...
-
Phillipson, Mia, ...
-
Hober, Sophia, P ...
-
Nilsson, Charlot ...
-
Mangsbo, Sara, 1 ...
-
Christ, Wanda
-
Klingstrom, Jona ...
-
Gordon, Max
-
Åberg, Mikael
-
Thalin, Charlott ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Immunologi inom ...
- Artiklar i publikationen
-
Vaccines
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Uppsala universitet
-
Karolinska Institutet